January 10, 2017. By Gordon Gibb.
Philadelphia, PA: As principles with Janssen Pharmaceuticals continued to maintain that pre-trial Risperdal settlements are one-offs and not an indication of any emerging strategy, Janssen nonetheless settled a Risperdal lawsuit Friday before what would have been the seventh Risperdal gynecomastia trial had a chance to start.Read [ Seventh Risperdal Gynecomastia Case Settled Prior to Trial ]
December 29, 2016. By Jane Mundy.
Baltimore, MD: Johnson & Johnson is accused of targeting Risperdal marketing towards children and teenagers, to the extent that the antipsychotic drug has been prescribed to treat anxiety in children. But some of those boys who developed gynecomastia, a non-cancerous increase in the size of male breast tissue, now suffer from depression and chances are, J&J has a drug for that too.Read [ Risperdal for Kids Reaps Big Bucks—but for how long? ]
December 10, 2016. By Gordon Gibb.
Philadelphia, PA: With the $70 million Risperdal settlement from back in the summer continuing to reverberate, the sixth bellwether Risperdal lawsuit as part of the Pennsylvania Mass Tort is underway. The plaintiff, a Nebraska man, is claiming in his Risperdal gynecomastia lawsuit that Risperdal is responsible for the growth of male breast tissue.Read [ Latest Bellwether Risperdal Lawsuit Underway in Philadelphia ]
November 29, 2016. By Heidi Turner.
Philadelphia, PA: Plaintiffs following recent Risperdal litigation news might be forgiven for thinking the latest awards and settlements are good news. After all, a Risperdal lawsuit that went to trial in the summer resulted in a $70 million jury award. Other awards to plaintiffs alleging they suffered Risperdal side effects also hit the million-dollar mark. And Janssen Pharmaceuticals reportedly settled a lawsuit for a confidential amount in recent months.Read [ Risperdal Awards Add Up For Plaintiffs ]
November 22, 2016. By Gordon Gibb.
Philadelphia, PA: Any assumption that Johnson & Johnson (J&J) settled a recent Risperdal lawsuit just prior to trial while peering through the rear-view mirror at a large plaintiff verdict from July is pure speculation, according to the attorney representing the plaintiffs. Still, with a $70 million judgement awarded to a Risperdal gynecomastia plaintiff just four months ago, such an assumption is understandable.Read [ Don’t Read Anything into $70 Million Risperdal Settlement: Attorney ]
November 2, 2016. By Lucy Campbell.
Santa Clara, CA: A settlement has been reached in a lawsuit against the makers of the antipsychotic drug Risperdal (Risperidone). The suit, had it gone to court, would have been the sixth to be heard in a mass torte pending against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. In the last case that went to court, the jury, awarded the plaintiff $70 million. This latest suit was settled for a confidential amount.Read [ Settlement Reached in Risperdal Gynecomastia Lawsuit ]
October 27, 2016. By Gordon Gibb.
Philadelphia, PA: A legal battle currently raging over a statute of limitations for Risperdal lawsuits is being watched closely by plaintiffs facing the potential loss of their Risperdal gynecomastia lawsuit over interpretations as to when plaintiffs could have become aware of a potential association between Risperdal and Growing Male Breasts.Read [ Risperdal Side Effects Lawsuits Hinge on Appeal of Limitations Ruling ]
October 24, 2016. By Jane Mundy.
Minneapolis, MN: Derek has been following the Risperdal lawsuits and subsequent settlements diligently, particularly the recent case that resulted in a $70 million award. Like Adam Yount, Derek'is son has also developed female breast tissue. Unlike Yount, he hasn’t yet been diagnosed with gynecomastia.Read [ Risperdal – The Cost of Teasing and Statute of Limitations ]
September 18, 2016. By Jane Mundy.
Los Angeles, CA: Last month Johnson & Johnson was ordered to pay $18 million because it caused health care providers to submit false claims to Medicare and other federal health care programs. The device in question is a sinus spacer product, but it’s almost a repeat performance of J&J’s Risperdal claims and subsequent settlement.Read [ Johnson & Johnson’s Tale of Two Profit Makers: Risperdal and Relieva ]
September 9, 2016. By Gordon Gibb.
Washington, DC: It’s not that difficult to understand why Johnson & Johnson, the makers of anti-psychotic drug Risperdal (risperidone), would take lawsuits and criticism in stride given the revenues generated by the blockbuster drug: reported by Bloomberg to be $24.2 billion in worldwide sales from 2003 through 2010. In that sense, any corresponding Risperdal lawsuits over Risperdal side effects such as the growth of male breasts, or risk-taking activity beyond the perimeters of regulatory boundaries, could be seen as simply a cost of doing business.Read [ Thousands of Risperdal Lawsuit Allege Risperdal Side Effects ]